"Under the terms of the collaboration, Unilife has granted Amgen...

"Under the terms of the collaboration, Unilife has granted Amgen exclusive rights to Unilife’s wearable injectors within select drug classes for use with certain Amgen assets, while preserving rights previously granted to other Unilife customers. Unilife has also granted Amgen non-exclusive rights to all proprietary Unilife delivery systems within the therapeutic areas of oncology, inflammation, bone health, nephrology, cardiovascular and neuroscience."

This is open ended in Unilife's favour, preserves existing (upcoming?) Agreements, and if "inflammation, bone health" is amgens Humira biosimilar, that could be a lot of volume.